Nkarta Inc

NASDAQ NKTX

Data sourced from

and

Download Data

Nkarta Inc Short-Term Debt to Total Assets Ratio 2 year CAGR for the quarter ending March 31, 2024: 13.50%

Nkarta Inc Short-Term Debt to Total Assets Ratio 2 year CAGR is 13.50% for the quarter ending March 31, 2024, a -64.36% change year over year. The short-term debt to total assets ratio measures the proportion of short-term debt to total assets of a company. It is calculated by dividing the short-term debt by the total assets. This ratio indicates the extent to which short-term debt contributes to the company's total asset structure. A higher ratio suggests a higher level of short-term debt relative to total assets. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.

Nkarta Inc Short-Term Debt to Total Assets Ratio for the quarter ending March 31, 2023 was 0.01, a 53.51% change year over year.
Nkarta Inc Short-Term Debt to Total Assets Ratio for the quarter ending March 31, 2022 was 0.01, a 23.83% change year over year.
Nkarta Inc Short-Term Debt to Total Assets Ratio for the quarter ending March 31, 2021 was 0.01, a -82.97% change year over year.
Nkarta Inc Short-Term Debt to Total Assets Ratio for the quarter ending March 31, 2020 was 0.04.

NASDAQ: NKTX

Nkarta Inc

CEO	Mr. Paul J. Hastings
IPO Date	July 10, 2020
Location	United States
Headquarters	6000 Shoreline Court, South San Francisco, CA, United States, 94080
Employees	150
Sector	Healthcare
Industry	Biotechnology

Description

Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis. It also develops NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands, which is in Phase I clinical trial for the treatment of r/r acute myeloid leukemia or higher risk myelodysplastic syndromes, as well as for solid tumors. In addition, the company develops NKX070, targeting the CD70 tumor antigen to treat solid and liquid tumors; and NK+T cell therapy for use in the treatment of oncology, autoimmune disease, or infectious disease. It has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.

Key trends